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OBJECTIVE—Poor glycemic control, elevated triglycerides,
and albuminuria are associated with vascular complications in
diabetes. However, few studies have investigated combined
associations between metabolic markers, diabetic kidney dis-
ease, retinopathy, hypertension, obesity, and mortality. Here, the
goal was to reveal previously undetected association patterns
between clinical diagnoses and biochemistry in the FinnDiane
dataset.
RESEARCH DESIGN AND METHODS—At baseline, clinical
records, serum, and 24-h urine samples of 2,173 men and 2,024
women with type 1 diabetes were collected. The data were
analyzed by the self-organizing map, which is an unsupervised
pattern recognition algorithm that produces a two-dimensional
layout of the patients based on their multivariate biochemical
proﬁles. At follow-up, the results were compared against all-
cause mortality during 6.5 years (295 deaths).
RESULTS—The highest mortality was associated with advanced
kidney disease. Other risk factors included 1) a proﬁle of insulin
resistance, abdominal obesity, high cholesterol, triglycerides,
and low HDL2 cholesterol, and 2) high adiponectin and high LDL
cholesterol for older patients. The highest population-adjusted
risk of death was 10.1-fold (95% CI 7.3–13.1) for men and
10.7-fold (7.9–13.7) for women. Nonsigniﬁcant risk was observed
for a proﬁle with good glycemic control and high HDL2 choles-
terol and for a low cholesterol proﬁle with a short diabetes
duration.
CONCLUSIONS—The self-organizing map analysis enabled de-
tailed risk estimates, described the associations between known
risk factors and complications, and uncovered statistical pat-
terns difﬁcult to detect by classical methods. The results also
suggest that diabetes per se, without an adverse metabolic
phenotype, does not contribute to increased mortality. Diabetes
57:2480–2487, 2008
P
atients with type 1 diabetes are susceptible to
severe microvascular complications such as pro-
liferative retinopathy and chronic kidney disease,
which are often accompanied by cardiovascular
disease and premature death (1,2). Currently, the risk
assessment and diagnostics rely on the urine albumin
excretion, serum creatinine, and lipid proﬁle (3,4). In
many cases, however, the biochemical measurements are
treated as independent factors without explicit attention
to the overall metabolic imbalance behind the complica-
tions. Although the risk factors for cardiovascular disease
and diabetes complications have been veriﬁed statistically
in large clinical studies (5–7), the overall picture on the
mutual relationships and their relevance for risk assess-
ment remains fragmented.
The metabolic syndrome (8) is one attempt to describe
the co-occurrence of vascular complications and insulin
resistance, but so far its applicability to type 1 diabetes
and its exact deﬁnition remain controversial (9,10). More-
over, gradually developing conditions, such as cardiovas-
cular disease, do not present a physiologically clear border
between health and disease, so quantitative risk assess-
ment tools are needed to augment and even replace
discrete differential categorizations (11). Hence, we are
developing new approaches to attain more accurate phe-
notypes without excessive cost, both through high-
throughput analytics (12,13) and computational methods
(14,15).
In this work, we develop an analysis framework based
on the self-organizing map and statistically veriﬁed visual-
izations (13,16,17) for a large clinical study. Our goal is to
characterize typical phenotypes (or metabolic proﬁles)
that can be associated with high or low mortality during
several years of follow-up. We do not question the role of
albuminuria as the primary marker of increased risk, but
we aim for a more comprehensive metabolic description
of the conditions that manifest as albumin excretion. We
show how numerous biochemical variables from serum
and urine can be integrated under one statistical model
while maintaining interpretability of the results, and we
also demonstrate how nonlinear multivariate statistics can
reveal complex phenotypes that are difﬁcult to detect by
classical methods.
RESEARCH DESIGN AND METHODS
Patients with type 1 diabetes were recruited by the Finnish Diabetic Nephrop-
athy Study (FinnDiane), a nationwide multicenter effort to identify genetic and
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2480 DIABETES, VOL. 57, SEPTEMBER 2008clinical risk factors for diabetic nephropathy. Diagnostic criteria for type 1
diabetes included age of onset 35 years and transition to insulin treatment
within a year of onset. Four patients were excluded because of insufﬁcient
biochemical data. The design was cross-sectional (n  4,197), but with
longitudinal records of albuminuria and clinical events before baseline and
with all-cause mortality data available after an average of 6.5 years of
follow-up from baseline (25,714 patient-years). The study protocol was in
accordance with the Declaration of Helsinki and approved by the local ethics
committee in each of the participating centers.
Biochemical data came both from centrally organized measurements (90%
of values) and from local healthcare centers and hospitals (10%). When both
were available, the centrally measured value was used. The pattern of missing
values was regular (online appendix 1, available at http://dx.doi.org/10.2337/
db08-0332), but no signiﬁcant sampling bias was detected.
Clinical deﬁnitions. Data on medication, cardiovascular status, and diabetes
complications were registered by a standardized questionnaire, which was
completed by the patient’s attending physician according to the medical ﬁle.
Vitality was obtained from the national registry maintained by the Population
Register Center of Finland.
The classiﬁcation of renal status was made centrally according to urinary
albumin excretion rate (AER) in at least two of three consecutive overnight or
24-h urine samples. Patients on renal replacement therapy (dialysis or
transplantation) were classiﬁed as having end-stage renal disease (ESRD).
Absence of nephropathy was deﬁned as normoalbuminuria (AER 20 g/min
or 30 mg/24 h), whereas overt diabetic kidney disease (DKD) was obtained
by pooling macroalbuminuria (AER 200 g/min or 300 mg/24 h) and ESRD.
The intermediary range was deﬁned as microalbuminuria (20  AER  200
g/min or 30  AER  300 mg/24 h). Timed albumin excretion from the latest
24-h urine collection for each patient was also available, and it was used as a
biochemical variable in parallel with the longitudinal records of AER.
The metabolic syndrome was deﬁned as a score of 3 according to the
modiﬁed National Cholesterol Education Program Adult Treatment Panel III
criteria (10,13,18), where every patient with type 1 diabetes has an initial score
of 1 for hyperglycemia. Diabetic retinopathy (DRP) was deﬁned as present if
a patient had undergone laser treatment of the retina. Macrovascular disease
was deﬁned as a pooled end point of coronary heart disease, myocardial
infarction, stroke, and peripheral vascular disease. Blood pressure was
measured twice with 2-min intervals in the sitting position after a 10-min rest.
Biochemical measurements. Serum lipid and lipoprotein concentrations
were measured from fasting blood samples at the research laboratory of
Helsinki University Central Hospital, Division of Cardiology (Helsinki). Total
cholesterol and triglycerides were determined enzymatically using an auto-
analyzer (Cobas Mira or Mira Plus; ABX Diagnostics, Montpellier, France).
Total HDL and HDL3 cholesterol were determined enzymatically using an
assay reader (HTS 7000 Plus Bio; Perkin Elmer, Wellesley, MA). HDL2
cholesterol was calculated by subtracting HDL3 cholesterol from total HDL
cholesterol. LDL cholesterol was calculated according to the Friedewald
formula. Serum apolipoprotein A-I, A-II, and B concentrations were deter-
mined by immunoassays (Orion Diagnostica, Espoo, Finland). Serum and 24-h
urine creatinine (enzymatic), 24-h urine albumin (immunoturbidimetric),
C-reactive protein (radioimmunoassay), and C-peptide (radioimmunoassay)
were quantiﬁed at the Helsinki University Central Hospital Laboratory (Hel-
sinki). Adiponectin and mannan binding lectin were measured as previously
described (19,20). Twenty-four–hour urine urea (enzymatic), Na, and K (ion
selective electrode) were measured on a Cobas Integra analyzer (Hoffmann-La
Roche, Basel, Switzerland) by Medix Laboratories (Espoo, Finland). A1C was
determined by standardized assays at local healthcare centers and hospitals.
Statistical analyses. To characterize metabolic proﬁles and compare them
with the current clinical classiﬁcations, a self-organizing map was constructed
based on the biochemical variables only. Before analysis, variables that were
highly correlated (e.g., 24-h urine creatinine and urea) were pruned if
considered biologically redundant, which left 14 variables in the ﬁnal training
set (online appendix 1). The input data were rank-transformed (shifted and
scaled rank indexes from 1 to 1) for both sexes separately to ensure that
each variable had an identical value distribution irrespective of sex-speciﬁc
differences in absolute values. Simultaneously, the impact of outliers and
extreme values was attenuated. Missing values were ignored in the transfor-
mation but imputed from the preprocessed data by least-squares linear
regression before analysis.
The self-organizing map is an unsupervised pattern recognition method
(13,16) and was used here for automated comparisons between the multivar-
iate biochemical proﬁles. The resulting map layout of patients becomes such
that those who have similar proﬁles are as close to each other as possible,
whereas those who have different proﬁles are placed far apart on the map
(online appendix 2). Here, a 7  10 grid of hexagonal map units was chosen
with a Gaussian neighborhood function (60 patients per unit). The self-
organizing map algorithm was initialized based on the two ﬁrst principal
components of the input data and ﬁnished by the batch training procedure.
After the patients’ positions were computed, the map was colored accord-
ing to the patients’ characteristics (clinical variables) within different regions
(13). To verify that the results were statistically reliable, 10,000 random
colorings were computed by permuting the data values to obtain empirical P
values for each of the variables separately. The null distributions from the
permutation analysis were also the basis of the color scale in each ﬁgure, so
that the categorical and continuous variables, possibly with some data
missing, could be compared visually while maintaining the statistical inter-
pretation. In addition, 95% CIs were obtained by bootstrapping and are listed
in the text when available. The aforementioned techniques were also applied
to the biochemical variables, but because they were the inputs for the
self-organizing map, the null hypothesis was no longer valid. The respective P
values and CIs were thus omitted.
Relative risk of dying (Fig. 4) was estimated by ﬁrst computing the
colorings for age and for the frequency of deaths observed on each map unit
and then adjusting the estimated mortality against the expected mortality in
the respective age segment in the Finnish population, for men and women
separately, during the follow-up period. The unadjusted death percentages
and follow-up times are available in online appendix 3. The population history
was collected by Statistics Finland (http://www.stat.ﬁ).
The self-organizing map analysis was performed with the MeliKerion
software package for the Matlab/Octave programming environment (online
appendix 2). A web-based interface for the software is also available (http://
www.computationalmedicine.ﬁ/software). In-house scripts were used for the
data preprocessing and additional analyses. The computational analyses for
the study took 2 h on a workstation with a single-core 3.2 GHz CPU.
RESULTS
Initial analyses showed that the self-organizing map was
heavily inﬂuenced by the physiological differences be-
tween men and women. To avoid confounding effects, the
sex-speciﬁc features were eliminated by rank transforma-
tion (see RESEARCH DESIGN AND METHODS). Figure 1 illustrates
the sex distribution on the self-organizing map of the
preprocessed data and shows no spatial separation be-
tween men and women.
The patients’ locations on the map were determined by
their similarity to the self-organizing map proﬁles. The
proﬁles, in turn, were derived from the average properties
of the local population in the corresponding neighbor-
hood. During the training process, this reciprocal relation-
ship stabilized to a set of models, a number of which are
depicted in Fig. 1. For instance, patients in the southwest
corner (row 7, column 1) were characterized by a proﬁle
with good glycemic control (low A1C), high HDL2 choles-
terol, low apolipoprotein B, and low C-reactive protein.
Patients in the opposite corner in the northeast (2,10)
were summarized by a proﬁle of high levels of triglycerides
and low HDL2 cholesterol.
By examining several proﬁles from various parts of the
map the global features begin to emerge. For example,
serum creatinine is higher on the northern regions (1,1;
1,6; 2,10) if compared with the south (7,1; 7,10) and
apolipoprotein A-I is higher in the west (1,1; 7,1) compared
with the east (2,10; 7,10). Although with this many vari-
ables, the bar proﬁles are not the most visually effective
way to investigate the global properties, and thus the map
coloring approach was applied to better reveal the statis-
tical patterns.
Vascular complications and premature death. The
patients that are located on a given hexagonal unit deter-
mine the color for the respective area of the self-organiz-
ing map (13). Figure 2 depicts the spatial distributions of
clinical categories for the male patients. Not surprisingly,
the highest (47% [38–57%]) 10-year mortality is observed
near the highest DKD prevalence (84% [80–89%]) and is
coupled with a history of macrovascular complications
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and DKD prevalence (71% [65–77%]), but the coupling with
macrovascular complications remains (online appendix
4). The highest percentages of DRP coincide with DKD
and high mortality in the north, with 84% (79–88%) prev-
alence for men and 77% (72–83%) for women; on the
southern half of the map, less than one-third of patients
have DRP (Fig. 2D). The metabolic syndrome does not
predict death accurately because the highest percentages
(men, 88% [83–93%]; women, 86% [81–91%]) occur in the
northeastern corner (Fig. 2E), away from the areas with
the highest mortality. A detailed breakdown of the DKD
grades and the metabolic syndrome scores is available in
online appendix 3.
FIG. 1. Multivariate metabolic proﬁles of patients with type 1 diabetes. The ﬁgure depicts the distribution of men and women on the
self-organizing map that was constructed based on the listed biochemical variables. The self-organizing neural network algorithm places those
patients that have similar biochemical proﬁles close to each other and those that have differing proﬁles far apart on the map. The bar plots
illustrate the averaged proﬁle for patients that reside on a given hexagonal region. F, Sets of 10 men; E, sets of 10 women: this was done to avoid
excessive clutter from individual markers for each patient.
FIG. 2. Self-organizing map colorings of clinical features for men with type 1 diabetes. The map in Fig. 1 can be colored according to the
characteristics of the local residents within each hexagonal unit. The color scale indicates the deviation from population mean with respect to
the random ﬂuctuations that could be expected by chance. The numbers on selected units tell the local prevalence (binary variables) or mean
value (continuous variables) for that particular region. For plot A, which illustrates time-adjusted mortality, the random ﬂuctuations could
not be estimated using the standard procedure, hence the pseudocolors are different to avoid direct comparisons with the rest of the
colorings. The P values below the plots indicate the probability of observing equivalent regional variability for random data. *The metabolic
syndrome included variables that were also self-organizing map inputs, hence the P value is only suggestive. Colorings for women are
available in online appendix 4.
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the development of diabetes complications but do not fully
explain the deaths: Although the patients on the north-
western regions of the map are older (men, 44.3 years
[42.9–45.9 years]; women, 43.2 years [41.4–45.1 years]),
they have average mortality. The same regions are associ-
ated with lower insulin doses (men, 0.62 IU/kg [0.59–0.65
IU/kg]; women, 0.60 IU/kg [0.57–0.63 IU/kg]) and lower
A1C, especially toward the south (Fig. 2H and I). C-
peptide levels are negligible (10 pmol/l) in every map
region (Fig. 2J).
Systolic blood pressure is highest in the north (men, 147
mmHg [145–151 mmHg]; women, 142 mmHg [139–146
mmHg]) and is linked to high mortality (Fig. 2K and L).
Patients in the same regions are on medication, with up to
93% (90–96%) of men and 85% (81–90%) of women under
antihypertensive treatment (Fig. 2M). Abdominal obesity
is most prevalent in the northeastern parts of the map (Fig.
2N and O), with wide waist (men, 96 cm [94–98 cm];
women, 87 cm [85–89 cm]) and large BMI (men, 27.0 kg/m
2
[26.5–27.5 kg/m
2]; women, 26.6 kg/m
2 [26.1–27.3 kg/m
2]).
Neither of the anthropometric markers predict death
accurately.
Biochemical features of diabetes complications. The
complex nature of lipoproteins and lipids is explicitly
revealed by the self-organizing map (Fig. 3A–D; online
appendix 5). The metabolic syndrome region in the north-
east is characterized by the highest triglyceride concentra-
tion (men, 2.7 mmol/l; women, 2.2 mmol/l) and high LDL
and total cholesterol but low HDL2 cholesterol (men, 0.23
mmol/l; women, 0.32 mmol/l). Closer to the western cor-
ner, HDL2 is restored (men, 0.49 mmol/l; women, 0.67
mmol/l) with elevated LDL (men, 3.9 mmol/l; women, 3.7
mmol/l). Patients on the southern half have lower triglyc-
erides and cholesterol, except for HDL2, which exhibits an
ascending east-west pattern. Lipid-lowering treatment is
more common in the north but fails to explain the changes
in lipoprotein fractions (Fig. 3E).
The number of VLDL/IDL/LDL particles (apolipoprotein
B in Fig. 3G) is the highest in the metabolic syndrome
corner (men, 123 mg/dl; women, 126 mg/dl), with an
overall pattern similar to cholesterol and triglycerides.
Apolipoprotein A-I is related to HDL2 cholesterol, as
expected (Fig. 3F).
24-h urine albumin (Fig. 3H) is consistent with the DKD
classiﬁcation (Fig. 2C), and the highest serum creatinine
concentrations (men, 221 mol/l; women, 162 mol/l) are
found near the high-mortality regions (Figs. 1A and 3H).
This advanced DKD phenotype in the north is also asso-
ciated with decreased 24-h urine creatinine (men, 11.0
mmol; women, 8.2 mmol), elevated serum potassium
(men, 4.9 mmol/l; women, 4.7 mmol/l) and decreased 24-h
urine potassium (men, 50 mmol; women, 42 mmol) in Fig.
3J–L.
The highest adiponectin levels can be observed in the
north and northwest (men, 20 mg/l; women, 26 mg/l).
Albuminuria coincides with high adiponectin only on the
western quadrant; the metabolic syndrome corner in the
northeast shows a relative reduction in adiponectin (Fig.
3H) but higher serum C-reactive protein levels (men, 4.3
mg/l; women, 7.6 mg/l) in Fig. 3N. Mannan-binding lectin
concentrations exhibit no clear patterns (Fig. 3O).
High-risk metabolic phenotypes. The observations on
clinical and biochemical characteristics were summarized
by ﬁve model phenotypes. The ﬁve models do not repre-
sent patient clusters; they show a condensed version of
the colorings in Figs. 2 and 3 (see also online appendix 6).
Figure 4A depicts a phenotype with low A1C, high HDL2
cholesterol, and low triglyceride concentration, with very
few complications. Accordingly, the population-adjusted
risk of premature death remains nonsigniﬁcant. In the
north, total cholesterol, apolipoprotein B and 24-h urine
albumin are higher, along with higher age in Fig. 4B.T h e
risk of premature death is 3.8-fold (2.7–5.0) for men and
3.9-fold (2.4–5.7) for women on the map units 2,2 and
1,2.
FIG. 3. Colorings of biochemical variables on the self-organizing map. The map colorings were produced with the same procedure as in Fig. 2.
However, empirical P values are not available for the biochemical variables that were included in the self-organizing map training data. Colorings
for women are available in online appendix 5.
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is characterized by high serum creatinine, albuminuria,
and elevated adiponectin (Fig. 4C). For men, the 10-year
mortality peaks in this region (Fig. 2A), but after adjusting
by age, the 9.1-fold (7.3–10.4) risk is no longer the highest
on the map. For women, the highest 10.7-fold (7.9–13.7)
risk coincides with mortality (online appendix 4) but is
closer to the northeast corner.
The highest 10.1-fold (7.3–13.1) risk of death in male
patients is observed at the metabolic syndrome corner in
Fig. 4D. By deﬁnition, the phenotype is characterized by
wide waist, high triglycerides, and low HDL2 cholesterol.
Although the prevalence of DKD is high in these patients,
they exhibit the highest total cholesterol and apolipopro-
tein B concentrations, in contrast to the lower values in
Fig. 4C.
Diabetes duration is the shortest in the southeastern
regions, where mortality is low and relative risk nonsignif-
icant (Fig. 4E). Nevertheless, the phenotype shares low
HDL2 cholesterol with the northeast corner, which con-
tributes to the observed prevalence of the metabolic
syndrome. The two corners are separated by the triangle
of A1C, total cholesterol, and triglycerides, which are
elevated in the north.
A number of patients in the high-risk zone (Fig. 4F) have
normoalbuminuria despite otherwise adverse biochemical
proﬁles. Aside from 24-h urine albumin and serum creati-
nine, antihypertensive treatment is the most signiﬁcant
discriminating factor, with 23% of normoalbuminuric men
(14% of women) but 90% of those with DKD (P  1.1 
10
52 for men, P  3.8  10
54 for women) on medication.
The next best discriminator is diabetes duration: Nor-
moalbuminuric men in the high-risk zone have 13 years
shorter duration (P  1.9  10
12) and women have 11
years shorter duration (P  2.3  10
16) than the “meta-
bolic peers” with DKD.
DISCUSSION
The life expectancy for a patient with type 1 diabetes
depends heavily on the development of kidney disease and
the concurrent incidence of macrovascular events
(1,7,21,22). Our analyses with the self-organizing map
conﬁrmed this and provided carefully adjusted estimates
for the relative risk of premature death. In addition, we
also revealed direct associations between the metabolic
features and several clinical outcomes.
Urine albumin is biologically highly variable, which has
raised questions about its role as an early marker of
complications (23). Also, there is continuous discussion
on the exact cutoffs that deﬁne the clinical DKD catego-
ries, which in turn have signiﬁcant impact on the treat-
ment decisions at an individual level (24). Could
albuminuria be supplemented by other sources of infor-
mation? Much work is being concentrated at ﬁnding new
biomarkers for kidney disease, and some candidates have
been found (25–27), although many of them are compared
against existing albuminuria and hence do not directly
lead to better accuracy in subclinical risk assessment.
Genetic susceptibility has also been investigated (28–32),
but conclusive results are still lacking, and it is uncertain
whether genetic testing will have clinical applications in
the near future. Considering the slow development of
these complications, the substantial individual and envi-
ronmental variation, and difﬁculties in exact phenotyping,
it may be too optimistic to expect any single factor to be
decisive in the traditional reductionist fashion (33). Our
attention has therefore shifted back to the known biomar-
kers and risk factors but with a more comprehensive
approach.
Multivariate exploratory analysis has been previously
applied to dyslipidemia, the metabolic syndrome, and type
2 diabetes (34–36), but most of these studies were focused
on the associations between variables (linear factoriza-
tion) rather than on the individuals. Here, we described
FIG. 4. Metabolic phenotypes and risk of premature death. The relative risk of death for men and women was estimated against the expected
sex-speciﬁc mortality in Finland. A–E: Five model phenotypes were constructed based on observations from Figs. 1–3. The models do not
represent distinct clusters in the dataset, but they summarize the characteristics of patients around the highlighted area to make the
discussion in relation to Figs. 2 and 3 easier. F: A high-risk region was highlighted for detailed comparisons of DKD categories (results are
listed in text).
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diversity of the patients’ biochemical proﬁles and combin-
ing the results with existing clinical knowledge. The
phenotypes do not represent patient clusters because that
would imply detectable boundaries between the metabolic
states (see online appendix 6). Instead, the data reﬂect
different stages of gradual damage in a continuous and
time-dependent manner, which prevents clear categoriza-
tions in a cross-sectional population-based study.
The self-organizing map has been applied previously in
the analysis of spectroscopic data (13,14), in molecular
conformation analysis (37), in studies of gene-metabolite
interactions (38), and in multivariate assessment of insulin
resistance (17), among others. Although the sensitivity
was demonstrated also in this study, the nonlinear algo-
rithm may also lead to the typical problems of multivariate
modeling such as overﬁtting and false positives (39). Here,
the number of samples was large compared with the
number of explanatory variables (4,197 patients vs. 14
variables), which already makes the model less prone to
exaggerate weak results. Modest-sized maps with
smoothed estimates were chosen, and to be absolutely
sure, only the biochemical variables were used as inputs;
this way, the statistical signiﬁcance of the observed vari-
ability for the clinical features on the self-organizing map
could be veriﬁed.
The self-organizing map is an indeterministic method in
the sense that a small change in the input data may change
the shapes of observed patterns signiﬁcantly. We therefore
recommend testing with different map sizes and subsets
of the input data to determine the biologically relevant
interpretations. The problem is not so much in the robust-
ness of the algorithm, but with the fact that nonbiological
effects such as sampling bias, differences in data collection
methods and laboratory protocols over time may produce
data-driven artifacts in clinical studies with a long history.
The highest relative risk of premature death (10.1-fold
for men and 10.7-fold for women) was associated with a
metabolic proﬁle that shared features from DKD (high 24-h
urine albumin and serum creatinine) and from the meta-
bolic syndrome (high triglycerides, low HDL cholesterol,
and wide waist). Albuminuria was the common risk factor,
as expected, but the two sides were also distinguished by
adiponectin, which was higher on the map units domi-
nated by microvascular complications (Figs. 2 and 3,
northwest vs. northeast), and C-reactive protein, which
was higher in the metabolic syndrome corner.
Earlier studies already showed that female sex and renal
insufﬁciency are associated with higher adiponectin levels
(40) and that DKD is associated with increased C-reactive
protein levels (41). Similar results have been obtained with
respect to microangiopathy (19,42) and long diabetes
duration (43). Unlike C-reactive protein, adiponectin is
considered to be inversely related to obesity and dyslipi-
demia, and low levels have been linked to cardiovascular
disease (44,45). By considering only the correlation be-
tween the metabolic syndrome and DKD, one could con-
clude that this is not true in type 1 diabetes. The self-
organizing map analysis, however, was able to show that
the link between adiponectin and the metabolic syndrome
(or abdominal obesity and low HDL cholesterol) is, in fact,
present, although concealed by the overall increase of
adiponectin due to diabetes complications. Also, C-reac-
tive protein seemed to have a more complex role than
classical analyses would suggest: The highest levels were
not observed for DKD speciﬁcally but for patients with
high scores of the metabolic syndrome.
The incomplete overlap between DKD and metabolic
syndrome was also visible from the lipid-centered perspec-
tive. The northwest and northeast quadrants of the color-
ings in Figs. 2 and 3 indicated that the lipid proﬁle of a
typical patient with advanced DKD was located between a
high HDL phenotype with microvascular complications
and a high triglyceride–low HDL phenotype with the
metabolic syndrome (Fig. 4B–D). Survival bias (ESRD plus
metabolic syndrome underrepresented) may have been
the cause for the reduction in cholesterol and triglyceride
concentrations in Fig. 4C, because mortality was high.
Altered nutrition and other effects due to ESRD are other
likely causes, but the data are insufﬁcient for a ﬁnal
conclusion.
The diverse picture of different lipid proﬁles in various
manifestations of microvascular and macrovascular dis-
eases sheds light on the heterogeneous results from pre-
vious studies (46–49). For instance, the role of HDL
metabolism in the development of DKD has not yet been
determined conclusively; this study suggests that low
HDL2 cholesterol is coupled with abdominal obesity and
increased insulin requirement but not necessarily with
persistent albuminuria. On the other hand, high HDL2
cholesterol may represent a marker of good glycemic
control and a low prevalence of complications at higher
age (Fig. 2, southwest and western regions).
The clinical material was extensive from the cross-
sectional phase, but the exact causes of death were not
available for the prospective part. Nevertheless, the pop-
ulation registry in Finland is highly accurate, and the
vitality status itself was reliable. From previous studies, it
is known that most premature deaths related to type 1
diabetes are caused by cardiovascular events (2,9), which
is plausible also in this study: A history of macrovascular
disease coincided with the high-mortality regions (Fig. 2A
and B).
On one hand, a clear relationship between DKD and
mortality exists, but on the other hand, there seems to be
a dual nature to the vascular complications, with a quartet
of poor glycemic control, adverse lipid proﬁle, abdominal
obesity, and insulin resistance on one corner (50) and a
high HDL, high adiponectin, leaner phenotype with micro-
vascular complications on the other. When these two
collide, the risk of death peaks according to our present
and previous results (13). Many of these observations have
already been reported, but here all the data were viewed
within a single statistical framework that not only de-
scribed the known risk factors in their metabolic context
but also showed additional details that would have been
laborious to detect by classical methods. We therefore
expect that the multivariate approach, as applied here, will
enable more rapid and thorough investigations of large
clinical datasets, give grounds to novel hypotheses of the
pathology of diabetes complications, and open new per-
spectives into the complex interactions between meta-
bolic risk factors.
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